Anna Strongin1, Theo Heller2, Dan Doherty3,4, Ian A Glass3,4, Melissa A Parisi5, Joy Bryant6, Peter Choyke7, Baris Turkbey7, Kailash Daryanani8, Deniz Yildirimli6, Meghana Vemulapalli9, Jim C Mullikin9, May C Malicdan6, Thierry Vilboux6,10, William A Gahl6,11,12, Meral Gunay-Aygun6,12,13. 1. Digestive Diseases Branch. 2. Translational Hepatology Section, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 3. Department of Pediatrics, University of Washington. 4. Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA. 5. Eunice Kennedy Shriver National Institute of Child Health and Human Development. 6. Medical Genetics Branch, National Human Genome Research Institute. 7. Molecular Imaging Program, National Cancer Institute. 8. Radiology and Imaging Sciences, Clinical Center. 9. NIH Intramural Sequencing Center (NISC), National Human Genome Research Institute, National Institutes of Health, Bethesda, MD. 10. Inova Translational Medicine Institute, Falls Church, VA. 11. NIH Undiagnosed Diseases Program, Common Fund, Office of the Director. 12. Office of the Clinical Director, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD. 13. Johns Hopkins University School of Medicine, Department of Pediatrics and McKusick-Nathans Institute of Genetic Medicine, Baltimore, MD.
Abstract
BACKGROUND AND AIMS: Joubert Syndrome (JS) is a rare, inherited, ciliopathy defined by cerebellar and brainstem malformations and is variably associated with liver, kidney, and ocular dysfunction. This study characterizes the hepatic findings in JS and identifies factors associated with probable portal hypertension. METHODS: Hundred individuals with JS were prospectively evaluated at the National Institutes of Health Clinical Center. Laboratory tests, imaging, and DNA sequencing were performed. Patients were stratified based on the spleen length/patient height ratio as a marker of splenomegaly, used as a surrogate for probable portal hypertension. RESULTS: Forty-three patients (43%) had liver involvement based on elevated liver enzymes and/or liver hyperechogenicity and/or splenomegaly. None of the patients had macroscopic liver cysts or bile duct dilatation. Based on the spleen length/patient height ratio, 13 patients were stratified into a probable portal hypertension group. We observed significant elevations in alkaline phosphatase (269 vs 169 U/L, P ≤ 0.001), alanine aminotransferase (92 vs 42 U/L, P = 0.004), aspartate aminotransferase (77 vs 40 U/L, P = 0.002), and gamma-glutamyl transferase (226 vs 51 U/L, P ≤ 0.001) in the probable portal hypertension group. Platelets were lower in the probable portal hypertension cohort (229 vs 299 × 10 cells/μL, P = 0.008), whereas synthetic function was intact in both groups. Probable portal hypertension was also more prevalent in patients with kidney disease (P = 0.001) and colobomas (P = 0.02), as well as mutations in the TMEM67 gene (P = 0.001). CONCLUSIONS: In JS, probable portal hypertension is associated with abnormal hepatic enzymes, as well as presence of kidney disease, coloboma, and/or mutation in TMEM67. These findings may allow early identification of JS patients who have or are more likely to develop liver disease.
BACKGROUND AND AIMS: Joubert Syndrome (JS) is a rare, inherited, ciliopathy defined by cerebellar and brainstem malformations and is variably associated with liver, kidney, and ocular dysfunction. This study characterizes the hepatic findings in JS and identifies factors associated with probable portal hypertension. METHODS: Hundred individuals with JS were prospectively evaluated at the National Institutes of Health Clinical Center. Laboratory tests, imaging, and DNA sequencing were performed. Patients were stratified based on the spleen length/patient height ratio as a marker of splenomegaly, used as a surrogate for probable portal hypertension. RESULTS: Forty-three patients (43%) had liver involvement based on elevated liver enzymes and/or liver hyperechogenicity and/or splenomegaly. None of the patients had macroscopic liver cysts or bile duct dilatation. Based on the spleen length/patient height ratio, 13 patients were stratified into a probable portal hypertension group. We observed significant elevations in alkaline phosphatase (269 vs 169 U/L, P ≤ 0.001), alanine aminotransferase (92 vs 42 U/L, P = 0.004), aspartate aminotransferase (77 vs 40 U/L, P = 0.002), and gamma-glutamyl transferase (226 vs 51 U/L, P ≤ 0.001) in the probable portal hypertension group. Platelets were lower in the probable portal hypertension cohort (229 vs 299 × 10 cells/μL, P = 0.008), whereas synthetic function was intact in both groups. Probable portal hypertension was also more prevalent in patients with kidney disease (P = 0.001) and colobomas (P = 0.02), as well as mutations in the TMEM67 gene (P = 0.001). CONCLUSIONS: In JS, probable portal hypertension is associated with abnormal hepatic enzymes, as well as presence of kidney disease, coloboma, and/or mutation in TMEM67. These findings may allow early identification of JS patients who have or are more likely to develop liver disease.
Authors: Woon Geon Shin; Sang Hoon Park; Sun-Young Jun; Jae One Jung; Joon Ho Moon; Jong Pyo Kim; Kyoung Oh Kim; Cheol Hee Park; Tai Ho Hahn; Kyo-Sang Yoo; Jong Hyeok Kim; Choong Kee Park Journal: Gut Liver Date: 2007-12-31 Impact factor: 4.519
Authors: Thierry Vilboux; Daniel A Doherty; Ian A Glass; Melissa A Parisi; Ian G Phelps; Andrew R Cullinane; Wadih Zein; Brian P Brooks; Theo Heller; Ariane Soldatos; Neal L Oden; Deniz Yildirimli; Meghana Vemulapalli; James C Mullikin; May Christine V Malicdan; William A Gahl; Meral Gunay-Aygun Journal: Genet Med Date: 2017-01-26 Impact factor: 8.822
Authors: Ruxandra Bachmann-Gagescu; Jennifer C Dempsey; Sara Bulgheroni; Maida L Chen; Stefano D'Arrigo; Ian A Glass; Theo Heller; Elise Héon; Friedhelm Hildebrandt; Nirmal Joshi; Dana Knutzen; Hester Y Kroes; Stephen H Mack; Sara Nuovo; Melissa A Parisi; Joseph Snow; Angela C Summers; Jordan M Symons; Wadih M Zein; Eugen Boltshauser; John A Sayer; Meral Gunay-Aygun; Enza Maria Valente; Dan Doherty Journal: Am J Med Genet A Date: 2019-11-11 Impact factor: 2.802
Authors: RaeLynn Forsyth; Melissa A Parisi; Burak Altintas; May Christine Malicdan; Thierry Vilboux; Jasmine Knoll; Brian P Brooks; Wadih M Zein; William A Gahl; Camilo Toro; Meral Gunay-Aygun Journal: Am J Med Genet C Semin Med Genet Date: 2022-03-21 Impact factor: 3.359
Authors: Brian P Brooks; Wadih M Zein; Amy H Thompson; Maryam Mokhtarzadeh; Daniel A Doherty; Melissa Parisi; Ian A Glass; May C Malicdan; Thierry Vilboux; Meghana Vemulapalli; James C Mullikin; William A Gahl; Meral Gunay-Aygun Journal: Ophthalmology Date: 2018-07-25 Impact factor: 12.079